University of Michigan

University System of Maryland

Eastern Michigan University

Ludwig Institute for Cancer Research Limited

Human Genome Sciences, Inc.

American National Red Cross

T+ink, Inc.

Csl Limited

American Red Cross

B-creative Sweden Ab

Other

University of Utah Research Foundation

Wyeth

Zih Corporation

Henry Ford Health System

Daniel Lawrence

Enming Joe Su

Dudley Strickland

Manuel S Yepes

Ulf Eriksson

Cory Emal

Timothy A Coleman

Shih-Hon Li

Mark Warnock

Linda Fredriksson

Jacqueline Cale

Patrick J Dillon

Gregg A Hastings

Terrance Z Kaiserman

John D Gentile

Steven Martin Cohen

Ashley Reinke

Steingrimur P Stefansson

Ingrid Nilsson

Jeanne Ann Cupp

Michael K Fein

David Ginsburg

David LeRoy Crandall

Wayne A Border

Nancy A Noble

Steven T Olson

Joseph D Shore

Dell Paielli

Ann Marie Francis-Chmura

William P Fay

Steingrimor P Stefansson

Natalia Gorlatova

Gregory Abernathy

Maria Sandkvist

Michael K K Wong

Daniel T Eitzman

Provided herein are plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The disclosure includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.

Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use

A method of reducing an effect of stroke in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signaling.

Method of reducing the effect of a stroke comprising administering an inhibitor of vascular endothelial growth factor B (VEGF-B)

Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-&#x3b1; antagonist.

Methods and compositions for modulation of blood-neural barrier

The present disclosure is generally directed to methods of tracking stocked inventory, such as products or other items stocked on a store shelf or other storage space. The disclosure is also directed to devices and systems that may be utilized to carry out such methods.

Automatic sensing methods and devices for inventory control

Method of treating stroke by administering a compound that inhibits VEGF-B signaling in combination with a thrombolytic agent

The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.

Plasminogen activator inhibitor-1 inhibitors and methods of use thereof

Systems and methods for identifying one or more objects hung from a display peg are described herein. The system may include a display peg comprising a first and second electrically conductive terminal. An object comprising a resistive element may be hung from the display peg such that the resistive element is in electrical communication with the terminals. A source may be configured to provide a current that flows from the first terminal through the resistive element to the second terminal. An electronic device may be configured to detect the electrical current flowing from the second terminal. The system may be configured to identify the type of object depending on the detected electrical current.

System and method for identifying one or more objects hung from a display peg

The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.

Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism

Systems and methods for identifying one or more objects hung from a display peg are described herein. The system may include a display peg comprising a first and second electrically conductive terminal. An object comprising a resistive element having a preselected resistance may be hung from the display peg such that the resistive element is in electrical communication with the terminals. A source may be configured to provide a current that flows from the first terminal through the resistive element to the second terminal. An electronic device may be configured to detect the current flowing from the second terminal. The system may be configured to identify the type of object depending on the pre-selected resistance of the resistive element.

Growing community of inventors

Ann Arbor, MI, United States of America

Daniel Lawrence